Florence Joly

Active 1996–2025

169
Papers
25,081
Citations
85
h-index
164
i10-index

Citations

Citations per year for Florence Joly1998: 1 citations1999: 3 citations2000: 3 citations2001: 3 citations2002: 5 citations2003: 9 citations2004: 5 citations2005: 15 citations2006: 6 citations2007: 6 citations2008: 10 citations2009: 21 citations2010: 24 citations2011: 42 citations2012: 58 citations2013: 70 citations2014: 93 citations2015: 94 citations2016: 127 citations2017: 138 citations2018: 185 citations2019: 797 citations2020: 1,027 citations2021: 1,050 citations2022: 1,076 citations2023: 900 citations2024: 1,565 citations2025: 714 citations2026: 18 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,348 citing papers, 18.4% of this breakdownChina: 1,004 citing papers, 7.9% of this breakdownItaly: 971 citing papers, 7.6% of this breakdownFrance: 898 citing papers, 7% of this breakdownUnited Kingdom: 884 citing papers, 6.9% of this breakdownGermany: 615 citing papers, 4.8% of this breakdownSpain: 549 citing papers, 4.3% of this breakdownCanada: 526 citing papers, 4.1% of this breakdownNetherlands: 426 citing papers, 3.4% of this breakdownAustralia: 393 citing papers, 3.1% of this breakdownJapan: 383 citing papers, 3% of this breakdownBelgium: 334 citing papers, 2.6% of this breakdown
0%18.4%Other 26.9%

Fields

  • Medicine76.4%
  • Biochemistry, Genetics and Molecular Biology12.8%
  • Immunology and Microbiology5.9%
  • Nursing1%
  • Neuroscience0.6%
  • Materials Science0.5%
  • Other2.8%

Topics

  • Ovarian cancer diagnosis and treatment7%
  • PARP inhibition in cancer therapy6.5%
  • Cancer Immunotherapy and Biomarkers3.4%
  • Endometrial and Cervical Cancer Treatments3%
  • Bladder and Urothelial Cancer Treatments2.8%
  • Cancer survivorship and care2.7%
  • Other74.6%

Coauthors

All papers

Open in search
  1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson and 21 more - The Lancet Oncology 2017 cited by 1,863

  2. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian and 17 more - The Lancet 2017 cited by 1,704

  3. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , - Annals of Oncology 2022 cited by 638

  4. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brieuc Sautois, Jean‐Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sérgio Jobim Azevedo, GISELE LOPES MARINHO, João Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, André P. Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, José Luis Leal, Francisco Francisco, Carolina Ibáñez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Fléchon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross‐Goupil, Stéphane Culine, Yohann Loriot, Gwénaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David G. Pfister, Carsten Ohlman, Michael Stöeckle, Manfred P. Wirth, Anja Lorch, Guenter Niegisch, Peter J. Goebell, Martin Boegemann, Axel S. Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian A. Thomas, Thomas Hoefner, András Telekes, Judit Kósa, János Révész, Gyorgy Bodoky, Tibor Csőszi, András Csejtei, Lajos Géczi, Ágnes Ruzsa, Zsuzsanna Kolonics, József Erfán, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger and 158 more - The Lancet Oncology 2021 cited by 648

  5. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio González-Martı́n, Viola Heinzelmann‐Schwarz, Florence Joly, J.W. Kim, Frédéric Kridelka, Jonathan A. Ledermann, Domenica Lorusso, Sven� Mahner, W. Glenn McCluggage, Iain A. McNeish, Mikio Mikami, Mansoor Raza Mirza, Philippe Morice, Shibani Nicum, Siel Olbrecht, Dearbhaile M. O’Donnell, Patricia Pautier, François Planchamp, Sandro Pignata, Denis Querleu, Isabelle Ray‐Coquard, Alexandros Rodolakis, Jalid Sehouli, Fatih Selçukbırıcık, Cristiana Sessa, Nilanchali Singh, David S.P. Tan, D. Timmerman, Germana Tognon, Jacobus van der Velden, Ignace Vergote, Petronella O. Witteveen, Alain G. Zeimet - Annals of Oncology 2019 cited by 1,165

  6. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2023 cited by 442

  7. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors

    Authors: , , , , , , , , - Annals of Oncology 2019 cited by 679

  8. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sophie Abadie‐Lacourtoisie, Claudia Andreetta, Nerea Anzizar, Daiseuke Aoki, Maria-Pilar Barretina-Ginesta, Marco Johannes Battista, Charlotte Béllier, Anne Gry Bentzen, Dominique Berton, Bertrand Billemont, Line Bjørge, Maria Bjurberg, Destin Black, Alessandra Bologna, Elena Ioana Braicu, Cláudia Casanova, Radoslav Chekerov, Annick Chevalier, Juan Cueva, Bastian Czogalla, Nicolas Delanoy, Dominik Denschlag, Oscar Derke, Michael Eichbaum, Takayuki Enomoto, Carmen Esteban, Michel Fabbro, Tanja Fehm, Annamaria Ferrero, Markus C. Fleisch, Anne Floquet, Antonio Frassoldati, Lydia Gaba, Angiolo Gadducci, Yolanda García García, Elena Geuna, Eva Guerra, Lars Hanker, Anne‐Claire Hardy‐Bessard, Philipp Harter, Kosei Hasegawa, Kristina Hellman, Ana Herrero, Felix Hilpert, Dionyssios Katsaros, M. Koegel, Anthoula Koliadi, Jean‐Emmanuel Kurtz, Bjoern Lampe, Andrea Alberto Lissoni, Alain Lortholary, Giorgia Mangili, Laura Mansi, Frederik Marmé, Cara Mathews, William Mina, Shinichiro Minobe, Katherine Moxley, Shoji Nagao, Ornella Nicoletto, Koji Nishino, Hiroshi Nishio, Shin Nishio, Ana Oaknin, Michaela Onstad, Beatriz Pardo, José Alejandro Pérez Fidalgo, Carmela Pisano, Andrés Poveda, Julia Caroline Radosa and 21 more - The Lancet 2023 cited by 209

  9. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli and 127 more - The Lancet Oncology 2020 cited by 498

  10. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  11. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 867

  12. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José Alejandro Pérez Fidalgo, Sandro Pignata, Pedro T. Ramírez, Isabelle Ray‐Coquard, Ignacio Romero, Giovanni Scambia, Jalid Sehouli, Ronnie Shapira‐Frommer, Sudha Sundar, David S.P. Tan, Çağatay Taşkıran, Willemien J. van Driel, Ignace Vergote, François Planchamp, Cristiana Sessa, Anna Fagotti - Annals of Oncology 2024 cited by 284

  13. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

    Authors: , , , , , , , , , , - European Urology 2020 cited by 247

  14. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean-Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fabio A. Franke, Fabricio Augusto Martinelli de Oliveira, Andrea Juliana Pereira de Santana Gomes, Hélio Pinczowski, Daniel D'Almeida Preto, Luis Eduardo Zucca, Giuliano Santos Borges, Andre M. Murad, Fred Saad, Kim N. Chi, Yves Fradet, Neil E. Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stephane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean-Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz-Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus J.M. van den Eertwegh, Johannes Voortman, Maureen J. Aarts, Jourik A. Gietema, Choung-Soo Kim, Young-Deuk Choi, Byung-Ha Chung, Rustem A. Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, José Pablo Maroto, Jesús García-Donás, Juan Francisco Rodríguez Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, David Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente Vázquez, Enrique Castellanos, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich and 34 more - The Lancet Oncology 2022 cited by 186

  15. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on behalf of the ATALANTE/ENGOT-ov29 Investigators, Jean‐Emmanuel Kurtz, Sophie Abadie‐Lacourtoisie, Cyril Abdeddaim, J. Alexandre, P. Augereau, D. Avenin, M. Azémar, Nabil Baba-Hamed, Olivia Bally, Jérôme Barrière, Fernando Bazán, Dominique Berton, Nathalie Bonichon-Lamichhane, Nathalie Bonnin, Elouen Boughalem, R. Boustany Grenier, Pierre-Emmanuel Brachet, Fabien Brocard, Émilie Bultot-Boissier, Maria Cappiello-Bataller, H. Castanie, L. Chaigneau, Camille Chakiba, Dorothée Chocteau-Bouju, Pierre Combe, Aurélie Comte, Elodie Coquan, Cristina Costan, P. Cottu, L. Crouzet, H. Curé, Jérôme Dauba, Hussain Dawood, Laure De Cock, T. De La Motte Rouge, C. Debelleix, Catherine Delbaldo, Martin Demarchi, Marion Deslandres, Raymond Despax, Véronique D’Hondt, Anne Françoise DILLIES-LEGRAIN, A Donnadieu, C. Dubot, Jean Marc Extra, Michel Fabbro, Claire Falandry, F. Fiteni, Anne Floquet, Philippe Follana, Jean‐Sébastien Frenel, G. Freyer, D. Garbay-Decoopman, Céline Gavoille, V. Girre, Laurence Gladieff, F. Goldwasser, Alain Gratet, Jean‐Christophe Grenier, Anne‐Claire Hardy‐Bessard, Pierre‐Etienne Heudel, Florence Joly, A. Jouinot, Emilie Kalbacher, Marie‐Christine Kaminsky, Laurence Lancry-Lecomte, R. Largillier, Fanny Le Du, Alexandra Léary and 89 more - Journal of Clinical Oncology 2023 cited by 103

  16. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ali Hasbini, Guilhem Bousquet, M. Soulié - The Lancet Oncology 2013 cited by 740

  17. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begoña Mellado, Omi Parikh, Peter Schatteman, Stéphane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio V. Scagliotti, Giovanni Schinzari, Jae‐Lyun Lee, Mikhail Shkolnik, Mark T. Fleming, Monika Joshi, Peter H. O’Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, R. Delva, Frédéric Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, C. Cebotaru, Ignacio Durán, Víctor Moreno, José Luis Perez‐Gracia, Álvaro Pinto, Wen-Pin Su, Shian‐Shiang Wang, John D. Hainsworth, Ian D. Schnadig, Sandhya Srinivas, Nicholas J. Vogelzang, Wolfgang Loidl, Johannes Meran, M. Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, S. Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauß, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora N. Sternberg, Sun Young Rha, Iurie Bulat, А. А. Измайлов, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, M.I. Sáez, Isabel Syndikus and 6 more - The Lancet Oncology 2022 cited by 169

  18. BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 331

  19. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sven� Mahner, Alexander Reuß, Andreas du Bois, Christoph Grimm, Christian Marth, Regina Berger, Nicole Concin, Ting‐Chang Chang, Kazunori Ochiai, Val Gebski, Alison Davis, Philip Beale, Ignace Vergote, Frédéric Kridelka, Hannelore Denys, Vincent Vandecaveye, Francisco José Cândido dos Reis, Maria Del Pilar Estevez-Diz, Gavin Stuart, Helen Mackay, Mark S. Carey, David Cibula, Pavel Dundr, Oliver Dorigo, Jonathan S. Berek, Dearbhaile M. O’Donnell, Feras Abu Saadeh, Ingrid Boere, Christianne Lok, Pluvio Coronado, Nelleke Ottevanger, David S.P. Tan, Joseph Ng, Antonio Gonzalez Martin, Ana Oaknin, Andrés Poveda, Alejandro Perez Fidalgo, Alejandro Rauh-Hain, Karen H. Lu, Carlos López-Zavala, Eva María Gómez-García, Isabelle Ray-Coquard, Xavier Paolettí, Jean‐Emmanuel Kurtz, Florence Joly, Bénédicte Votan, Michael A. Bookman, Kathleen Moore, Rebecca C. Arend, Keiichi Fujiwara, Hiroyuki Fujiwara, Kosei Hasegawa, Ilan Bruchim, Dalia Tsoref, Katsutoshi Oda, Aikou Okamoto, Takayuki Enomoto, Dayana Michel, Hee‐Seung Kim, Jung‐Yun Lee, Asima Mukhopadhyay, Dionyssios Katsaros, Nicoletta Colombo, Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Elise C. Kohn, Jungmin Lee, Iain A. McNeish, Shibani Nicum and 16 more - The Lancet Oncology 2022 cited by 142

  20. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 cited by 182

  21. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 193

  22. Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

    Authors: , , , , , , , , - New England Journal of Medicine 2011 cited by 746

  23. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

    Authors: , , , , , , , , , , , , , , , , , , , - European Urology 2015 cited by 462

  24. A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2014 cited by 206